NewAmsterdam Pharma (NAMS) Consolidated Net Income (2023 - 2026)
NewAmsterdam Pharma (NAMS) posted Consolidated Net Income of -$48.4 million for Q1 2026, up 35.35% sequentially from -$74.9 million in Q4 2025, and down 22.55% YoY from -$62.5 million in Q1 2025.
NewAmsterdam Pharma (NAMS) Consolidated Net Income (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Consolidated Net Income for 4 years, with the latest figure at -$48.4 million in Q1 2026.
- Quarterly Consolidated Net Income fell 22.55% year-over-year to -$48.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$212.7 million (down 13.54% YoY) and the FY2025 annual result came in at -$151.2 million, up 37.4% from the prior year.
- Consolidated Net Income grew to -$48.4 million in Q1 2026 per NAMS's latest filing, from -$74.9 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at -$16.6 million in Q3 2024 and troughed at -$93.8 million in Q1 2024.
- A 4-year average of -$52.7 million and a median of -$47.8 million in 2023 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2024 and 2025: Consolidated Net Income surged 64.68% in 2024, then tumbled 332.54% in 2025.
- Over 4 years, Consolidated Net Income stood at -$49.5 million in 2023, then sank by 86.34% to -$92.2 million in 2024, then rose by 18.72% to -$74.9 million in 2025, then surged by 35.35% to -$48.4 million in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$48.4 million, -$74.9 million, and -$72.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - | -64.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -64.14 Mn |
| Mar 31, 2026 | -48.44 Mn |
| Dec 31, 2025 | -74.92 Mn |
| Sep 30, 2025 | -72.01 Mn |
| Jun 30, 2025 | -17.36 Mn |
| Mar 31, 2025 | -39.53 Mn |
| Dec 31, 2024 | -92.18 Mn |
| Sep 30, 2024 | -16.65 Mn |
| Jun 30, 2024 | -39.01 Mn |
| Mar 31, 2024 | -93.77 Mn |
| Dec 31, 2023 | -49.47 Mn |
| Sep 30, 2023 | -47.13 Mn |
| Mar 31, 2023 | -42.02 Mn |